KOREA WHO

Jang Myung-ho is the CEO of GI Innovation, jointly leading the company with co-CEO Hong Jun-ho.

He was born on June 3, 1968.

He studied biochemistry at Hanyang University, where he also earned a master’s degree in the same field. He then obtained a Ph.D. in immunology from the Graduate School of Osaka University in Japan.

Jang served as a professor for eight years at the Immunology Frontier Research Center of Osaka University Medical School, a globally recognized institution in the field of immunology, becoming the first Korean to do so.

After returning to South Korea, he worked as a senior researcher at the Institute for Basic Science (IBS). He also served as a scientific advisor at Genexine and as Chief Scientific Officer (CSO) at Progen.

In 2017, he founded GI Innovation. He initially served as CSO until 2021 and returned as CEO in April 2025.

Motivated by a belief in preventing “medical poverty,” he established a company focused on developing immuno-oncology treatments. He is now concentrating on improving the company’s performance through licensing-out achievements.

#JangMyungHo #GIInnovation #immunology #biotechstartup #OsakaUniversity #immunotherapy #IBS #KoreanScientist #biopharma #oncology